Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Impact of Ambulatory Physiological Stimulation of the Efferent Limb Prior to Ileostomy Closure on Colorectal Microbiota Composition and Histopathological Findings (STIMIC)

15 de junho de 2026 atualizado por: Romina Pena, Hospital Clinic of Barcelona

The STIMIC Trial: A Multicenter Randomized Control Trial Evaluating the Impact of Ambulatory Physiological Stimulation of the Efferent Limb Prior to Ileostomy Closure on Colorectal Microbiota Composition and Histopathological Findings

BACKGROUND Loop ileostomies are a type of stoma frequently used to protect high-risk colorectal anastomoses (surgical reconnection of the intestines), for example following rectal cancer resection. Temporary diversion of intestinal transit does not reduce the risk of anastomotic failure, but it does lower the morbidity and mortality associated with potential pelvic sepsis. Unfortunately, a second surgical procedure is required to restore intestinal continuity, and this carries its own risk of complications, the most common being postoperative ileus (temporary paralysis of bowel motility associated with abdominal distension, absence of bowel movements, nausea, and vomiting), which occurs in up to 20% of cases.

Several strategies have been proposed to reduce this problem, including stimulation of the efferent limb of the ileostomy (the part that is connected to the unused colon). This intervention consists of instilling a substance through the efferent limb of the ileostomy into the colon, simulating natural intestinal transit. It emerged as a harmless alternative aimed at reversing changes in the excluded colon in preparation for restoration of intestinal continuity. Several Spanish studies have investigated this technique, concluding that it is safe and significantly reduces the rate of postoperative ileus, thereby shortening hospital stay. Regarding the mechanism by which this intervention may be effective, there are studies investigating the changes that occur during diversion of intestinal transit:

  1. Histopathology: reduced muscular contractility and the presence of intestinal villi in the efferent intestinal limb and excluded colon, which improve once intestinal flow is restored.
  2. Microbiome: significant loss of microbiota in the defunctionalized colon, which progressively recovers with natural intestinal transit and reintroduction of a fiber-rich diet.

Structural and microbiota-related changes favor the development of diversion colitis, a condition associated with erratic bowel habits once intestinal transit is restored. In an attempt to reverse this condition, several products have been tested for stimulation of the efferent limb of the ileostomy: probiotics, short chain fatty acids, saline solution with a thickening agent, and the patient's own intestinal contents, a well-tolerated and effective technique, in some cases superior to saline-based alternatives.

Overall, the available evidence is of low quality due to the limited number of patients studied and protocol variability. For this reason, we propose the implementation of a protocol for stimulation of the distal ileostomy limb prior to ileostomy closure, either with saline solution and thickening agent (the most widely described technique in the literature) or physiological stimulation using the patient's own intestinal contents.

The protocol consists of several sessions in which the instilled volume is progressively increased. This intervention will be performed on an outpatient basis, once daily, during the two weeks prior to surgery.

This process promotes the onset of bowel movements through the anus, which progressively become more formed and less frequent, approaching a more normal bowel habit. Only minor adverse effects have been described with this technique, including cramp-like abdominal pain in 27.6% of sessions. Recently, a nationwide study confirmed the favorable clinical outcomes following distal ileostomy limb stimulation before ileostomy closure. However, to our knowledge, no studies have evaluated its effect on intestinal microbiota.

HYPOTHESIS Distal limb stimulation of the ileostomy before its closure helps in the recovery of the colorectal microbiome and tissue. This associates with lower postoperative complications, specially postoperative ileus.

OBJECTIVES To gain knowledge regarding changes in intestinal microbiota composition before and after stimulation, in order to better understand recovery of intestinal function following this procedure. We will also analyze outcomes after ileostomy closure following efferent limb stimulation, determining the incidence of postoperative complications, particularly postoperative ileus.

METHODOLOGY

Patients will be randomly assigned to one of three groups:

  1. Control (no intervention other than the usual preoperative protocol)
  2. Stimulation with serum and thickener
  3. Stimulation with own stoma output

Samples will be collected in all patients:

  1. Stoma output
  2. Stool, before stimulation, if performed
  3. Stool, after stimulation, if performed
  4. Stool, a month after surgery

For a group of patients, the ones recruited at Hospital Clínic, rectal biopsies will also be collected before and after stimulation, to compare the effect of the treatment in the colonic tissue. We will collect clinical data during the whole process regarding postoperative complications.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Estimado)

90

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Romina Pena, MD
  • Número de telefone: +34 617333153
  • E-mail: PENA@clinic.cat

Estude backup de contato

  • Nome: Miguel Pera, MD, PhD
  • Número de telefone: 5559 +34 932275400
  • E-mail: PERA@clinic.cat

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Descrição

Inclusion criteria:

  1. Patients 18 yo and older, with a loop ileostomy after colorectal surgery for malignant or benign disease and a barium enema that rules out colorectal anastomotic leak or stenosis.
  2. Patients must be self-sufficient in their stoma care or dispose of assistance by a family member or healthcare provider.
  3. Patients must reside no further than 50km from the hospital and dispose of postoperative home-assistance by a family member or healthcare provider.

Exclusion criteria:

  1. Patients with a terminal ileostomy or a closed distal limb, inaccesible to preoperative stimulation.
  2. Patients with the diagnosis of inflammatory bowel disease.
  3. Patients incapable of comprehending or signing the informed consent.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Ciência básica
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Sem intervenção: Control
No efferent limb stimulation.
Comparador Ativo: Serum stimulation
Efferent limb stimulation with serum and thickener.
The intervention has been described in previous studies, but the investigation of the microbiome changes associated with the obtained clinical results hasn't been described to date. Also, a study with three arms hasn't been published to date.
Outros nomes:
  • efferent limb stimulation
  • physiological stimulation
Comparador Ativo: Physiological stimulation
Efferent limb stimulation with the patient's own stoma output.
The intervention has been described in previous studies, but the investigation of the microbiome changes associated with the obtained clinical results hasn't been described to date. Also, a study with three arms hasn't been published to date.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Changes in colorectal microbiome before and after efferent limb stimulation prior to stoma closure.
Prazo: From enrollment to the end of follow-up at 3 months.
Descriptive analysis of the microbiome profiles of the three groups of patients (control, stimulation with serum, stimulation with own stoma output).
From enrollment to the end of follow-up at 3 months.
Changes in colorectal tissue before and after efferent limb stimulation prior to stoma closure.
Prazo: From the time of first biopsy (before stimulation) to the second one (surgery day).
Description of the tissue obtained by biopsy of the rectum, before and after stimulation of the ileostomy.
From the time of first biopsy (before stimulation) to the second one (surgery day).

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Postoperative complications after stoma closure.
Prazo: From the surgery (ileostomy closure) to 30 days follow-up.
Incidence of postoperative ileus and surgical site infection.
From the surgery (ileostomy closure) to 30 days follow-up.
Functional outcomes after efferent limb stimulation (LARS score)
Prazo: From enrollment to the end of follow-up a 3 months.

Description of the funcional (defecatory) outcomes after ileostomy closure.

LARS (Low Anterior Resection Syndrome) score: total score ranges from 0-42 points (0-20 is equivalent no LARS, 21-29 points to minor LARS, and 30-42 to major LARS).

From enrollment to the end of follow-up a 3 months.
Functional outcomes after efferent limb stimulation (Vaizey score)
Prazo: From enrollment to the end of follow-up at 3 months.

Description of the funcional (defecatory) outcomes after ileostomy closure.

Vaizey score (also known as the St. Mark's Incontinence Score): total score ranges from 0 (perfect continence) to 24 points (severe incontinence).

From enrollment to the end of follow-up at 3 months.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Romina Pena, MD, Hospital Clinic of Barcelona

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de junho de 2026

Conclusão Primária (Estimado)

1 de dezembro de 2027

Conclusão do estudo (Estimado)

1 de março de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

26 de maio de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

8 de junho de 2026

Primeira postagem (Real)

10 de junho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

17 de junho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

15 de junho de 2026

Última verificação

1 de junho de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • HCB/2026/0615

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

All IPD that underlie results in a publication.

Prazo de Compartilhamento de IPD

Beginning 1 month and ending 1 year after the publication of results.

Critérios de acesso de compartilhamento IPD

IPD and supporting information of this study might be accessed by fellow researchers with a future study, related to our published findings. Researchers must submit a request for data sharing by contacting the principal investigator, who will also be the corresponding author in the future published data. The request to access IPD will be reviewed by the principal investigator (Romina Pena).

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • CIF
  • CSR

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever